pharmabiz.com | Dr Reddy's Labs scrip outperforms BSEHC, touches yearly high of pharmabiz.com DRL has already pushed four biosimilars viz, rituximab, filgrastim, darbepoetin alpha and peg-filgrastim in the market. To consolidate its position in biosimilars, DRL entered into an alliance with Merck Serono, a division of Merck KGaA, Germany during ... |
